Detalles de la búsqueda
1.
Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
Br J Haematol
; 185(1): 53-64, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30723894
2.
"Enjoy glass of wine before eating:" a randomized trial to test the orexigenic effects of this advice in advanced cancer patients.
Support Care Cancer
; 24(9): 3739-46, 2016 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-27039205
3.
Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer.
Cancer
; 121(6): 883-92, 2015 Mar 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25377507
4.
Sex-dependent Prognosis of Patients with Advanced Soft Tissue Sarcoma.
Clin Cancer Res
; 30(2): 413-419, 2024 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-37831066
5.
Sex- and Co-Mutation-Dependent Prognosis in Patients with SMARCA4-Mutated Malignancies.
Cancers (Basel)
; 15(10)2023 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37345003
6.
TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma.
JCO Precis Oncol
; 7: e2200570, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-37163715
7.
Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit.
Commun Med (Lond)
; 3(1): 14, 2023 Feb 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36750617
8.
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.
Cancer Res Commun
; 3(7): 1335-1349, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37497337
9.
Improving Time to Molecular Testing Results in Patients With Newly Diagnosed, Metastatic Non-Small-Cell Lung Cancer.
JCO Oncol Pract
; 18(11): e1874-e1884, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36191286
10.
TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Differentially Associated With Sidedness-Dependent Prognosis in Metastatic Colorectal Cancer.
J Clin Oncol
; 40(2): 171-179, 2022 01 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34843402
11.
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.
Invest New Drugs
; 28(1): 91-7, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19238328
12.
A University of Chicago consortium phase II trial of SB-715992 in advanced renal cell cancer.
Clin Genitourin Cancer
; 6(1): 21-4, 2008 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-18501078
13.
Multi-Institutional, Prospective Clinical Utility Study Evaluating the Impact of the 92-Gene Assay (CancerTYPE ID) on Final Diagnosis and Treatment Planning in Patients With Metastatic Cancer With an Unknown or Unclear Diagnosis.
JCO Precis Oncol
; 2: 1-12, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-35135112
14.
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
J Clin Oncol
; 35(19): 2184-2192, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28489511
15.
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
J Clin Oncol
; 23(25): 5929-37, 2005 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-16135464
16.
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.
Cureus
; 8(2): e513, 2016 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-27026837
17.
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance).
J Clin Oncol
; 33(15): 1660-5, 2015 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-25732163
18.
A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321.
J Thorac Oncol
; 10(1): 172-80, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25247339
19.
NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status.
J Thorac Oncol
; 9(8): 1146-53, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25157767
20.
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.
Clin Cancer Res
; 20(2): 490-8, 2014 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-24178622